Outlook Therapeutics (OTLK) Current Deferred Revenue (2015 - 2019)
Outlook Therapeutics (OTLK) posted quarterly Current Deferred Revenue of $2.3 million for Q2 2019, up 5.8% year-over-year from $2.2 million in Q2 2018, and little changed quarter-over-quarter from $2.3 million in Q1 2019.
Outlook Therapeutics (OTLK) Current Deferred Revenue (2015 - 2019) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Current Deferred Revenue for 5 consecutive years, with $2.3 million the latest figure, recorded in Q2 2019.
- In Q2 2019, Current Deferred Revenue rose 5.8% year-over-year to $2.3 million; the TTM figure through Jun 2019 stood at $2.3 million (up 5.8% YoY), while the FY2018 annual figure was $1.7 million, down 43.69% from the prior year.
- Current Deferred Revenue steadied at $2.3 million in Q2 2019 per OTLK's latest filing, from $2.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.1 million in Q3 2017 and bottomed at $1.2 million in Q3 2016.
- Historically, Current Deferred Revenue has averaged $2.0 million across 5 years, with a median of $2.0 million in 2015.
- Annual changes were most pronounced in 2017 — Current Deferred Revenue soared 154.63% — and 2018, when it plunged 43.69%.
- Outlook Therapeutics' Current Deferred Revenue stood at $2.0 million in 2015, then tumbled by 38.75% to $1.2 million in 2016, then jumped by 126.82% to $2.8 million in 2017, then slipped by 13.0% to $2.4 million in 2018, then declined by 2.39% to $2.3 million in 2019.
- Business Quant data shows OTLK's Current Deferred Revenue at $2.3 million in Q2 2019, $2.3 million in Q1 2019, and $2.4 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 2.34 Mn |
| Mar 31, 2019 | 2.34 Mn |
| Dec 31, 2018 | 2.39 Mn |
| Sep 30, 2018 | 1.74 Mn |
| Jun 30, 2018 | 2.21 Mn |
| Mar 31, 2018 | 2.68 Mn |
| Dec 31, 2017 | 2.75 Mn |
| Sep 30, 2017 | 3.09 Mn |
| Jun 30, 2017 | 1.21 Mn |
| Mar 31, 2017 | 1.21 Mn |
| Dec 31, 2016 | 1.21 Mn |
| Sep 30, 2016 | 1.21 Mn |
| Jun 30, 2016 | 1.98 Mn |
| Mar 31, 2016 | 1.98 Mn |
| Sep 30, 2015 | 1.98 Mn |